Cyclin-Dependent Kinase Modulators and Cancer Therapy

Genomics and Cancer Drug Resistance

(2012) Antonio S. Rodrigues et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias

(2011) J. E. Karp et al.   BLOOD

Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription

(2011) Sonal M. Manohar et al.   LEUKEMIA RESEARCH

Responses in Mantle Cell Lymphoma Cells to SNS-032 Depend on the Biological Context of Each Cell Line

(2010) R. Chen et al.   CANCER RESEARCH

Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases

(2010) Gaetano Romano et al.   CELL CYCLE

Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies

(2010) Christophe Le Tourneau et al.   EUROPEAN JOURNAL OF CANCER

Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma

(2010) Wei-Gang Tong et al.   JOURNAL OF CLINICAL ONCOLOGY

Toward the Development of Innovative Bifunctional Agents To Induce Differentiation and To Promote Apoptosis in Leukemia: Clinical Candidates and Perspectives

(2010) Ioannis S. Vizirianakis et al.   JOURNAL OF MEDICINAL CHEMISTRY

Selective Cyclin-Dependent Kinase Inhibitors Discriminating between Cell Cycle and Transcriptional Kinases

(2009) Józefa Węsierska-Gądek et al.   Annals of the New York Academy of Sciences

Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia

(2009) Rong Chen et al.   BLOOD

SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples

(2009) Andrew Conroy et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Chemoprevention of Mouse Intestinal Tumorigenesis by the Cyclin-Dependent Kinase Inhibitor SNS-032

(2009) A. Boquoi et al.   Cancer Prevention Research

R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis

(2009) Małgorzata Rogalińska et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease

(2009) Thomas S. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Cdk9/Cyclin T1 complex: A key player during the activation/differentiation process of normal lymphoid B cells

(2008) Giulia De Falco et al.   JOURNAL OF CELLULAR PHYSIOLOGY